Showing results (11-20 of 88) with videos related to

Sort By:
Pageof 9
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1993
Why women gain weight with adjuvant chemotherapy for breast cancerW Demark-Wahnefried, E P Winer, B K Rimer
The American Journal of Medicine|April 1, 1997
A review of hereditary breast cancer: from screening to risk factor modificationM A Warmuth, L M Sutton, E P Winer
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 2, 2012
Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes?I Vaz-Luis, E P Winer, N U Lin
Breast Disease|February 3, 2005
Quality of life issues among women undergoing high-dose chemotherapy for breast cancerA H Partridge, C A Bunnell, E P Winer
Journal of the American Dietetic Association|May 1, 1997
Weight gain in women diagnosed with breast cancerW Demark-Wahnefried, B K Rimer, E P Winer
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 1998
Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancerC Lindley, S Vasa, W T Sawyer, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1997
Pharmacokinetics and clinical impact of all-trans retinoic acid in metastatic breast cancer: a phase II trialL M Sutton, M A Warmuth, W P Petros, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 1999
Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study GroupP E Goss, E P Winer, I F Tannock, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 1, 2011
CMF revisited in the 21st centuryE Munzone, G Curigliano, H J Burstein, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 10, 2005
Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapyH J Burstein, G Lieberman, D J Slamon, et al.
Pageof 9